Lundbeckfonden is an independent non-profit private foundation located in Copenhagen, Denmark, established in 1954 by Grete Lundbeck. Its primary objective is to maintain and expand the activities of the Lundbeck Group while providing financial support for research in biomedical and natural sciences. The foundation operates under the supervision of the Danish Civil Affairs Agency and has its assets managed by a board of directors. Lundbeckfonden also oversees Lundbeckfond Ventures, an evergreen life science venture fund founded in 2009, which invests up to €50 million annually. This fund operates independently from the Lundbeck Foundation's controlling interests in various companies, focusing on generating returns to support the foundation's broader activities.
Kvantify, founded in 2022 and headquartered in Copenhagen, Denmark, specializes in quantum computing management software aimed at addressing complex computational challenges across various sectors, including life sciences, financial services, and logistics. The company's platform focuses on enhancing drug discovery processes by employing proprietary physics-based methods to improve the quality of compounds tested in laboratories. By providing advanced computational drug technology, Kvantify enables life sciences companies to accelerate small molecule research and obtain actionable results that significantly impact their operations.
Notify Therapeutics
Venture Round in 2023
Notify Therapeutics is focused on developing innovative therapies for the treatment of infertility, specifically targeting women who do not respond to standard hormone therapy. The company’s approach centers on the early and hormone-independent phase of egg maturation, utilizing drug-inducing factors that regulate the intracellular AKT pathway. This unique methodology aims to enhance ovarian follicle development in women with low ovarian reserves, thereby improving their chances of successful conception. By providing a non-hormonal alternative, Notify Therapeutics seeks to address the needs of infertile women while minimizing the risks associated with multiple pregnancies.
Women in Life Science Denmark
Grant in 2023
WiLD is a networking platform for women in senior positions in business and academia that is motivating and focused on science.
VarmX
Series B in 2023
VarmX is a pharmaceutical spin-off from the Leiden University Medical Center focused on developing and manufacturing therapeutic proteins aimed at restoring blood clotting in patients experiencing severe bleeding. The company's lead product, PseudoXa, is a modified recombinant human coagulation factor X designed to work effectively in the presence of direct factor Xa anticoagulants like rivaroxaban, apixaban, and edoxaban. These anticoagulants are widely used for preventing and treating thrombosis and stroke but can lead to dangerous bleeding as a side effect. PseudoXa addresses this critical issue by providing a means to stop and prevent bleeding, thereby enhancing the safety of anticoagulant therapies for millions of patients worldwide.
Lexeo Therapeutics
Series B in 2021
Lexeo Therapeutics is a biotechnology company specializing in adeno-associated virus (AAV)-mediated therapies for both rare and common diseases caused by single gene mutations. Headquartered in New York, the company maintains an integrated pipeline developed in collaboration with Weill Cornell Medicine's Department of Genetic Medicine. Lexeo focuses on advancing its clinical programs towards commercialization while continuing to research new therapies for various patient populations and unmet medical needs.
Aura Biosciences
Venture Round in 2021
Aura Biosciences, Inc. is a clinical-stage biotechnology company based in Cambridge, Massachusetts, focused on developing therapies to target and destroy cancer cells using viral nanoparticle conjugates. The company’s lead product, AU-011, utilizes viral nanoparticles modeled on the human papillomavirus, conjugated with infrared-activated small molecules, specifically for the treatment of ocular melanoma, a primary eye cancer. By employing nanotechnology, Aura aims to safely eliminate cancer locally, particularly in early-stage cases, to prevent progression to more severe forms of the disease, such as metastasis to the liver. Additionally, the company is advancing its bel-sar candidate for treating primary choroidal melanoma and exploring applications in bladder cancer. Founded in 2007, Aura Biosciences is committed to developing precision immunotherapies that preserve the function of organs affected by cancer.
Lexeo Therapeutics
Series A in 2021
Lexeo Therapeutics is a biotechnology company specializing in adeno-associated virus (AAV)-mediated therapies for both rare and common diseases caused by single gene mutations. Headquartered in New York, the company maintains an integrated pipeline developed in collaboration with Weill Cornell Medicine's Department of Genetic Medicine. Lexeo focuses on advancing its clinical programs towards commercialization while continuing to research new therapies for various patient populations and unmet medical needs.
Reneo Pharmaceuticals
Series B in 2020
Reneo Pharmaceuticals is a clinical-stage pharmaceutical company based in San Diego, California, that focuses on developing therapies for patients with rare genetic mitochondrial diseases. These conditions are linked to defects in energy metabolism, leading to issues such as muscle weakness and wasting. The company is developing REN001, an oral drug designed to modulate genes involved in mitochondrial function, aiming to enhance adenosine triphosphate (ATP) production, which is essential for cellular energy. By improving mitochondrial activity, Reneo seeks to enhance the daily functioning and quality of life for patients suffering from these disorders. Founded in 2014, Reneo Pharmaceuticals is committed to addressing the needs of individuals with orphan metabolic diseases.
VarmX
Series B in 2020
VarmX is a pharmaceutical spin-off from the Leiden University Medical Center focused on developing and manufacturing therapeutic proteins aimed at restoring blood clotting in patients experiencing severe bleeding. The company's lead product, PseudoXa, is a modified recombinant human coagulation factor X designed to work effectively in the presence of direct factor Xa anticoagulants like rivaroxaban, apixaban, and edoxaban. These anticoagulants are widely used for preventing and treating thrombosis and stroke but can lead to dangerous bleeding as a side effect. PseudoXa addresses this critical issue by providing a means to stop and prevent bleeding, thereby enhancing the safety of anticoagulant therapies for millions of patients worldwide.
Amplyx Pharmaceuticals
Series C in 2020
Amplyx Pharmaceuticals is a small molecule drug development company focused on creating innovative therapies for life-threatening infections, particularly in patients with compromised immune systems. Founded in 2006 and based in San Diego, California, the company specializes in developing oral and injectable anti-infective drugs, including antifungal agents aimed at treating invasive fungal infections caused by pathogens such as Candida and Aspergillus. Amplyx employs a unique platform approach that enhances the efficacy and reduces the toxicity of existing drugs by combining them with additional small molecules. This strategy addresses critical treatment needs in hospital settings and provides effective therapy options for patients after discharge, particularly those undergoing chemotherapy and other immunosuppressive treatments.
IO Biotech
Debt Financing in 2020
IO Biotech is a clinical-stage biopharmaceutical company focused on developing innovative immune therapies for cancer treatment. Utilizing its proprietary T-win technology platform, the company creates immune-modulating cancer vaccines that activate T cells specifically targeting immune-suppressive molecules. This approach aims to induce the immune system to disrupt multiple pathways responsible for tumor-induced immunosuppression. IO Biotech has a solid track record in advancing both preclinical and clinical compounds, with its two lead candidates targeting IDO and PD-L1 currently in clinical development, while several additional therapies remain in the preclinical stage.
SANIFIT
Series D in 2019
Sanifit Therapeutics S.A. is a clinical-stage biopharmaceutical company dedicated to developing treatments for progressive vascular calcification disorders. Its primary product, SNF472, is a novel small molecule aimed at treating calciphylaxis, a serious condition affecting patients undergoing dialysis. In addition to SNF472, the company's pipeline includes Lit-Control, a medical device designed to enhance the quality of life for patients with renal lithiasis through self-monitoring of urinary pH; ASB-01, an oral and dental health solution; SNF671, a food supplement for promoting bone health; and Phytech, an implant surface treatment that incorporates bioactive molecules. Founded in 2004 and headquartered in Palma de Mallorca, Spain, Sanifit also operates an office in San Diego, California, and has expanded its activities into Switzerland since its inception.
Reneo Pharmaceuticals
Series A in 2019
Reneo Pharmaceuticals is a clinical-stage pharmaceutical company based in San Diego, California, that focuses on developing therapies for patients with rare genetic mitochondrial diseases. These conditions are linked to defects in energy metabolism, leading to issues such as muscle weakness and wasting. The company is developing REN001, an oral drug designed to modulate genes involved in mitochondrial function, aiming to enhance adenosine triphosphate (ATP) production, which is essential for cellular energy. By improving mitochondrial activity, Reneo seeks to enhance the daily functioning and quality of life for patients suffering from these disorders. Founded in 2014, Reneo Pharmaceuticals is committed to addressing the needs of individuals with orphan metabolic diseases.
Imara
Series B in 2019
Imara, Inc. is a clinical-stage biopharmaceutical company based in Boston, Massachusetts, focused on developing and commercializing therapeutics for rare genetic disorders of hemoglobin, including sickle cell disease and beta-thalassemia. Founded in 2016, the company is advancing its lead product candidate, IMR-687, which is a highly selective small molecule inhibitor of PDE9. IMR-687 is designed as an oral, once-a-day treatment that aims to modify disease through a multimodal mechanism of action affecting various cell types, including red and white blood cells. Imara is dedicated to addressing the unmet medical needs of patients suffering from these serious hemoglobinopathies.
Snipr Biome
Series A in 2019
Snipr Biome ApS is a biotechnology company based in Copenhagen, Denmark, focusing on the development of CRISPR technology for the treatment of microbial diseases. Established in 2017, the company aims to revolutionize how such diseases are addressed by leveraging the adaptive immune system to create medicines that selectively target and eliminate harmful bacteria based on their specific DNA sequences. By utilizing a novel approach that subverts elements of the endogenous bacterial CRISPR machinery, Snipr Biome provides health professionals with innovative tools for targeted microbiome engineering, enhancing the precision and effectiveness of treatments for bacterial infections.
Tiburio Therapeutics
Series A in 2019
Tiburio Therapeutics, Inc. is a biotechnology company focused on developing and manufacturing medicines for diseases related to the endocrine system. Founded in 2018 and based in Cambridge, Massachusetts, the company is advancing clinical-stage compounds aimed at treating rare neuroendocrine tumors and endocrine diseases. Notably, Tiburio is developing TBR-760, which targets non-functioning pituitary adenoma using a dopamine-somatostatin chimeric molecule designed to shrink or halt tumor growth. Additionally, Tiburio is working on TBR-065 for other rare endocrine diseases, addressing significant patient needs in these underserved areas.
Trevi Therapeutics
Series C in 2019
Trevi Therapeutics, Inc. is a clinical-stage biopharmaceutical company based in New Haven, Connecticut, dedicated to developing and commercializing nalbuphine ER, an oral extended-release formulation. The company is focused on treating serious neurologically mediated conditions, specifically chronic pruritus, chronic cough in patients with idiopathic pulmonary fibrosis, and levodopa-induced dyskinesia in individuals with Parkinson's disease. Trevi is currently conducting a Phase 2b/3 clinical trial, known as the PRISM trial, for nalbuphine ER, targeting severe pruritus associated with prurigo nodularis. The conditions being addressed share similar underlying mechanisms that involve opioid receptors in both the central and peripheral nervous systems. Founded in 2011, Trevi Therapeutics aims to provide innovative treatment options for patients suffering from these challenging health issues.
DYSIS Medical
Venture Round in 2018
DYSIS Medical Ltd. is a medical device company based in Edinburgh, United Kingdom, specializing in imaging systems for the non-invasive, in-vivo detection of cancerous and pre-cancerous lesions. The company has developed the DYSIS Colposcope, a digital device that assesses the aceto-whitening reaction and presents the findings in an intuitive map format. In addition to the colposcope, DYSIS Medical offers a range of accessories, including both disposable and reusable specula, diathermy loops, and coagulation balls, as well as software for image data management and development of the DYSISmap. Founded in 2002 and rebranded in 2011, DYSIS Medical aims to improve early detection of cancers, potentially addressing significant healthcare challenges globally. The company maintains sales offices in Tampa, Florida; Edinburgh; and Athens, Greece.
Iconic Therapeutics
Venture Round in 2018
Iconic Therapeutics, Inc. is a biopharmaceutical company focused on developing innovative therapeutics for retinal diseases and cancer by leveraging tissue factor biology in processes such as angiogenesis and inflammation. The company's lead product, ICON-1, is a fusion protein designed to combat vision loss associated with age-related macular degeneration. Additionally, Iconic Therapeutics has developed hI-con1, a novel recombinant protein that targets tissue factor to activate the immune system, facilitating the destruction of pathological blood vessels linked to conditions like wet age-related macular degeneration and certain cancers. This approach not only promotes cell-mediated cytotoxicity but may also help reduce levels of vascular endothelial growth factor (VEGF), which plays a critical role in these diseases. Phase 1 clinical studies of hI-con1 have shown promising results without significant toxicities, indicating dose-related biological activity. Founded in 2002 and headquartered in South San Francisco, California, Iconic Therapeutics aims to transform scientific insights into effective treatments for serious health conditions.
Enterome
Debt Financing in 2018
Enterome SA is a biopharmaceutical company based in Paris, France, with an additional office in Cambridge, Massachusetts. Founded in 2008, the company specializes in developing innovative disease management solutions that leverage the understanding of the gut microbiome. Enterome focuses on creating biomarkers, companion diagnostics, and therapeutics targeted at microbiome-related diseases, including inflammatory bowel diseases and metabolic disorders. The company’s OncoMimic technology addresses cancer by mimicking tumor-associated antigens, thereby inducing a strong immune response against solid tumors. Enterome's drug candidates are designed to modulate the immune system and are currently advancing through clinical trials, with several programs in Phase 2 targeting challenging cancers such as glioblastoma, adrenal malignancies, and colorectal cancer. The company has formed a strategic collaboration with Takeda Pharmaceutical Company to enhance its research and development efforts.
Aura Biosciences
Series C in 2017
Aura Biosciences, Inc. is a clinical-stage biotechnology company based in Cambridge, Massachusetts, focused on developing therapies to target and destroy cancer cells using viral nanoparticle conjugates. The company’s lead product, AU-011, utilizes viral nanoparticles modeled on the human papillomavirus, conjugated with infrared-activated small molecules, specifically for the treatment of ocular melanoma, a primary eye cancer. By employing nanotechnology, Aura aims to safely eliminate cancer locally, particularly in early-stage cases, to prevent progression to more severe forms of the disease, such as metastasis to the liver. Additionally, the company is advancing its bel-sar candidate for treating primary choroidal melanoma and exploring applications in bladder cancer. Founded in 2007, Aura Biosciences is committed to developing precision immunotherapies that preserve the function of organs affected by cancer.
Atox Bio
Series F in 2017
Atox Bio Inc. is a biotechnology company based in Ness Ziona, Israel, with an additional office in North Carolina. Founded in 2003, the company specializes in developing immunomodulators aimed at treating critically ill patients suffering from severe infections and acute inflammatory conditions. Atox Bio focuses on novel therapies that target multiple pathways within both the adaptive and innate immune responses, which are crucial in managing infectious diseases, inflammatory disorders, and ischemia/reperfusion injuries. The company’s products are designed to address serious medical conditions with high morbidity and mortality, showing promising results in improving patient outcomes and reducing tissue damage during acute inflammatory events.
Cydan
Venture Round in 2017
Cydan is an orphan drug accelerator focused on developing therapies for patients with rare genetic diseases. The organization identifies and mitigates the risks associated with compounds that have therapeutic and commercial potential. Through a rigorous process, Cydan generates data to support the development of new therapies and the formation of new companies. Their experienced team leverages strong relationships with academia and patient advocacy groups, along with deep expertise in drug development and a proven track record of successful product commercialization. By guiding therapies through clinical, regulatory, and commercial development, Cydan aims to improve the lives of patients and families affected by rare diseases.
Amplyx Pharmaceuticals
Series C in 2017
Amplyx Pharmaceuticals is a small molecule drug development company focused on creating innovative therapies for life-threatening infections, particularly in patients with compromised immune systems. Founded in 2006 and based in San Diego, California, the company specializes in developing oral and injectable anti-infective drugs, including antifungal agents aimed at treating invasive fungal infections caused by pathogens such as Candida and Aspergillus. Amplyx employs a unique platform approach that enhances the efficacy and reduces the toxicity of existing drugs by combining them with additional small molecules. This strategy addresses critical treatment needs in hospital settings and provides effective therapy options for patients after discharge, particularly those undergoing chemotherapy and other immunosuppressive treatments.
Trevi Therapeutics
Series C in 2017
Trevi Therapeutics, Inc. is a clinical-stage biopharmaceutical company based in New Haven, Connecticut, dedicated to developing and commercializing nalbuphine ER, an oral extended-release formulation. The company is focused on treating serious neurologically mediated conditions, specifically chronic pruritus, chronic cough in patients with idiopathic pulmonary fibrosis, and levodopa-induced dyskinesia in individuals with Parkinson's disease. Trevi is currently conducting a Phase 2b/3 clinical trial, known as the PRISM trial, for nalbuphine ER, targeting severe pruritus associated with prurigo nodularis. The conditions being addressed share similar underlying mechanisms that involve opioid receptors in both the central and peripheral nervous systems. Founded in 2011, Trevi Therapeutics aims to provide innovative treatment options for patients suffering from these challenging health issues.
Spero Therapeutics
Series C in 2017
Spero Therapeutics, Inc. is a clinical-stage biopharmaceutical company based in Cambridge, Massachusetts, dedicated to developing innovative treatments for multi-drug resistant (MDR) bacterial infections and rare diseases. Founded in 2013, the company is advancing several product candidates, including tebipenem pivoxil hydrobromide, an oral carbapenem-class antibiotic aimed at treating MDR gram-negative infections in adults. Additionally, Spero is developing SPR206, an intravenous agent for MDR gram-negative infections in hospital settings, and SPR720, an oral antibiotic targeting pulmonary non-tuberculous mycobacterial disease. The company collaborates with various partners, including Meiji Seika Pharma to support tebipenem HBr's development and the Bill & Melinda Gates Medical Research Institute for SPR720. Spero Therapeutics employs a focused approach to drug development, emphasizing novel mechanisms to address the urgent need for effective therapeutics against serious bacterial infections.
scPharmaceuticals
Series B in 2017
scPharmaceuticals Inc. is a pharmaceutical company focused on developing and commercializing innovative therapeutic options for patients with serious medical conditions. The company’s lead product candidate, Furoscix, features a proprietary buffered formulation of furosemide delivered via the SmartDose drug delivery system, targeting congestion in patients with decompensated heart failure. In addition to Furoscix, scPharmaceuticals is advancing its product pipeline with scCeftriaxone, an antibiotic for infections from gram-positive and gram-negative organisms, and its scCarbapenem program, aimed at treating infections caused by gram-negative organisms. Founded in 2013 and headquartered in Burlington, Massachusetts, scPharmaceuticals aims to provide a convenient, safe, and effective alternative to intravenous drug administration through subcutaneous delivery, addressing the associated costs and risks. The company collaborates with West Pharmaceutical Services, Inc. to enhance the SmartDose system for Furoscix.
Enterome
Series D in 2017
Enterome SA is a biopharmaceutical company based in Paris, France, with an additional office in Cambridge, Massachusetts. Founded in 2008, the company specializes in developing innovative disease management solutions that leverage the understanding of the gut microbiome. Enterome focuses on creating biomarkers, companion diagnostics, and therapeutics targeted at microbiome-related diseases, including inflammatory bowel diseases and metabolic disorders. The company’s OncoMimic technology addresses cancer by mimicking tumor-associated antigens, thereby inducing a strong immune response against solid tumors. Enterome's drug candidates are designed to modulate the immune system and are currently advancing through clinical trials, with several programs in Phase 2 targeting challenging cancers such as glioblastoma, adrenal malignancies, and colorectal cancer. The company has formed a strategic collaboration with Takeda Pharmaceutical Company to enhance its research and development efforts.
BONESUPPORT
Venture Round in 2016
BONESUPPORT AB is a medical technology company based in Lund, Sweden, specializing in the development of injectable bioceramic bone graft substitutes aimed at treating fractures and bone voids resulting from trauma, infection, disease, or surgery. Founded in 1999, the company offers a range of products, including CERAMENT BONE VOID FILLER, CERAMENT G, and CERAMENT V. These products are designed to address various medical conditions such as chronic osteomyelitis and infected diabetic foot ulcers. CERAMENT G and CERAMENT V are antibiotic-eluting bone graft substitutes that enhance bone healing, utilizing gentamicin and vancomycin, respectively. BONESUPPORT operates additional locations in Frankfurt, Zurich, London, Boston, and Haryana, India, and is committed to improving the quality of life for patients with bone disorders through innovative biomaterial solutions.
Iconic Therapeutics
Series C in 2016
Iconic Therapeutics, Inc. is a biopharmaceutical company focused on developing innovative therapeutics for retinal diseases and cancer by leveraging tissue factor biology in processes such as angiogenesis and inflammation. The company's lead product, ICON-1, is a fusion protein designed to combat vision loss associated with age-related macular degeneration. Additionally, Iconic Therapeutics has developed hI-con1, a novel recombinant protein that targets tissue factor to activate the immune system, facilitating the destruction of pathological blood vessels linked to conditions like wet age-related macular degeneration and certain cancers. This approach not only promotes cell-mediated cytotoxicity but may also help reduce levels of vascular endothelial growth factor (VEGF), which plays a critical role in these diseases. Phase 1 clinical studies of hI-con1 have shown promising results without significant toxicities, indicating dose-related biological activity. Founded in 2002 and headquartered in South San Francisco, California, Iconic Therapeutics aims to transform scientific insights into effective treatments for serious health conditions.
Vtesse
Series A in 2016
Vtesse, Inc. is a biopharmaceutical company based in Gaithersburg, Maryland, focused on developing treatments for patients with rare diseases. The company is conducting clinical studies for VTS-270, aimed at treating Niemann-Pick disease type C (NPC), and is also engaged in pre-clinical discovery and development of additional therapies for NPC and other lysosomal storage diseases. Vtesse originated as the first spin-out from Cydan Development, an orphan-drug accelerator that identifies promising therapeutic programs. The company collaborates with the National Institutes of Health (NIH) to advance its clinical studies and is supported by a consortium of experienced investors. Vtesse's management team has a strong background, having participated in the development of over 20 approved drugs and vaccines, which underscores its commitment to addressing the needs of underserved patient populations.
Enterome
Series C in 2016
Enterome SA is a biopharmaceutical company based in Paris, France, with an additional office in Cambridge, Massachusetts. Founded in 2008, the company specializes in developing innovative disease management solutions that leverage the understanding of the gut microbiome. Enterome focuses on creating biomarkers, companion diagnostics, and therapeutics targeted at microbiome-related diseases, including inflammatory bowel diseases and metabolic disorders. The company’s OncoMimic technology addresses cancer by mimicking tumor-associated antigens, thereby inducing a strong immune response against solid tumors. Enterome's drug candidates are designed to modulate the immune system and are currently advancing through clinical trials, with several programs in Phase 2 targeting challenging cancers such as glioblastoma, adrenal malignancies, and colorectal cancer. The company has formed a strategic collaboration with Takeda Pharmaceutical Company to enhance its research and development efforts.
Imara
Series A in 2016
Imara, Inc. is a clinical-stage biopharmaceutical company based in Boston, Massachusetts, focused on developing and commercializing therapeutics for rare genetic disorders of hemoglobin, including sickle cell disease and beta-thalassemia. Founded in 2016, the company is advancing its lead product candidate, IMR-687, which is a highly selective small molecule inhibitor of PDE9. IMR-687 is designed as an oral, once-a-day treatment that aims to modify disease through a multimodal mechanism of action affecting various cell types, including red and white blood cells. Imara is dedicated to addressing the unmet medical needs of patients suffering from these serious hemoglobinopathies.
Spero Therapeutics
Series B in 2016
Spero Therapeutics, Inc. is a clinical-stage biopharmaceutical company based in Cambridge, Massachusetts, dedicated to developing innovative treatments for multi-drug resistant (MDR) bacterial infections and rare diseases. Founded in 2013, the company is advancing several product candidates, including tebipenem pivoxil hydrobromide, an oral carbapenem-class antibiotic aimed at treating MDR gram-negative infections in adults. Additionally, Spero is developing SPR206, an intravenous agent for MDR gram-negative infections in hospital settings, and SPR720, an oral antibiotic targeting pulmonary non-tuberculous mycobacterial disease. The company collaborates with various partners, including Meiji Seika Pharma to support tebipenem HBr's development and the Bill & Melinda Gates Medical Research Institute for SPR720. Spero Therapeutics employs a focused approach to drug development, emphasizing novel mechanisms to address the urgent need for effective therapeutics against serious bacterial infections.
Iconic Therapeutics
Series C in 2016
Iconic Therapeutics, Inc. is a biopharmaceutical company focused on developing innovative therapeutics for retinal diseases and cancer by leveraging tissue factor biology in processes such as angiogenesis and inflammation. The company's lead product, ICON-1, is a fusion protein designed to combat vision loss associated with age-related macular degeneration. Additionally, Iconic Therapeutics has developed hI-con1, a novel recombinant protein that targets tissue factor to activate the immune system, facilitating the destruction of pathological blood vessels linked to conditions like wet age-related macular degeneration and certain cancers. This approach not only promotes cell-mediated cytotoxicity but may also help reduce levels of vascular endothelial growth factor (VEGF), which plays a critical role in these diseases. Phase 1 clinical studies of hI-con1 have shown promising results without significant toxicities, indicating dose-related biological activity. Founded in 2002 and headquartered in South San Francisco, California, Iconic Therapeutics aims to transform scientific insights into effective treatments for serious health conditions.
IO Biotech
Series A in 2016
IO Biotech is a clinical-stage biopharmaceutical company focused on developing innovative immune therapies for cancer treatment. Utilizing its proprietary T-win technology platform, the company creates immune-modulating cancer vaccines that activate T cells specifically targeting immune-suppressive molecules. This approach aims to induce the immune system to disrupt multiple pathways responsible for tumor-induced immunosuppression. IO Biotech has a solid track record in advancing both preclinical and clinical compounds, with its two lead candidates targeting IDO and PD-L1 currently in clinical development, while several additional therapies remain in the preclinical stage.
Biom'Up
Series C in 2015
Biom'Up S.A. is a French company based in Saint-Priest that specializes in the development and commercialization of hemostatic products utilizing patented biopolymers and collagen technology. Established in 2005, Biom'Up designs, manufactures, and sells innovative medical devices that enhance surgical practices across various specialties, including orthopedic, spinal, cardiac, general, maxillofacial, and laparoscopic surgeries. Their flagship products, HEMOBLAST bellows and associated laparoscopic applicators, aim to simplify surgical procedures and improve patient outcomes by facilitating guided regeneration of soft tissues and bone. The company markets its offerings primarily in Europe and the United States.
SANIFIT
Series C in 2015
Sanifit Therapeutics S.A. is a clinical-stage biopharmaceutical company dedicated to developing treatments for progressive vascular calcification disorders. Its primary product, SNF472, is a novel small molecule aimed at treating calciphylaxis, a serious condition affecting patients undergoing dialysis. In addition to SNF472, the company's pipeline includes Lit-Control, a medical device designed to enhance the quality of life for patients with renal lithiasis through self-monitoring of urinary pH; ASB-01, an oral and dental health solution; SNF671, a food supplement for promoting bone health; and Phytech, an implant surface treatment that incorporates bioactive molecules. Founded in 2004 and headquartered in Palma de Mallorca, Spain, Sanifit also operates an office in San Diego, California, and has expanded its activities into Switzerland since its inception.
Spero Therapeutics
Series A in 2015
Spero Therapeutics, Inc. is a clinical-stage biopharmaceutical company based in Cambridge, Massachusetts, dedicated to developing innovative treatments for multi-drug resistant (MDR) bacterial infections and rare diseases. Founded in 2013, the company is advancing several product candidates, including tebipenem pivoxil hydrobromide, an oral carbapenem-class antibiotic aimed at treating MDR gram-negative infections in adults. Additionally, Spero is developing SPR206, an intravenous agent for MDR gram-negative infections in hospital settings, and SPR720, an oral antibiotic targeting pulmonary non-tuberculous mycobacterial disease. The company collaborates with various partners, including Meiji Seika Pharma to support tebipenem HBr's development and the Bill & Melinda Gates Medical Research Institute for SPR720. Spero Therapeutics employs a focused approach to drug development, emphasizing novel mechanisms to address the urgent need for effective therapeutics against serious bacterial infections.
Akamis Bio
Series C in 2015
Akamis Bio is a clinical-stage oncology company dedicated to advancing cancer treatment through its innovative Tumor-Specific Immuno-Gene Therapy (T-SIGn®) platform. The company develops a portfolio of therapeutics specifically targeting solid tumors, aiming to enhance patients' immune responses to recognize and eradicate cancer cells. By harnessing a proprietary intravenously administered viral platform, Akamis Bio focuses on delivering effective gene therapies that address the needs of cancer patients, striving to improve their quality of life and treatment outcomes.
Vtesse
Series A in 2015
Vtesse, Inc. is a biopharmaceutical company based in Gaithersburg, Maryland, focused on developing treatments for patients with rare diseases. The company is conducting clinical studies for VTS-270, aimed at treating Niemann-Pick disease type C (NPC), and is also engaged in pre-clinical discovery and development of additional therapies for NPC and other lysosomal storage diseases. Vtesse originated as the first spin-out from Cydan Development, an orphan-drug accelerator that identifies promising therapeutic programs. The company collaborates with the National Institutes of Health (NIH) to advance its clinical studies and is supported by a consortium of experienced investors. Vtesse's management team has a strong background, having participated in the development of over 20 approved drugs and vaccines, which underscores its commitment to addressing the needs of underserved patient populations.
Ziarco
Series B in 2014
Ziarco, Inc. is a biotechnology company founded in 2012 and based in Palo Alto, California. The company specializes in the development of therapeutic agents aimed at treating inflammatory and allergic diseases. Its primary focus is on inflammatory skin disorders, and its product pipeline includes a histamine H4 receptor antagonist program targeting various conditions such as asthma, allergic rhinitis, pruritus, skin diseases, and pain. Ziarco's innovations aim to provide effective treatment options for patients suffering from atopic dermatitis and psoriasis, enhancing their quality of life through improved therapeutic solutions.
Atox Bio
Series E in 2014
Atox Bio Inc. is a biotechnology company based in Ness Ziona, Israel, with an additional office in North Carolina. Founded in 2003, the company specializes in developing immunomodulators aimed at treating critically ill patients suffering from severe infections and acute inflammatory conditions. Atox Bio focuses on novel therapies that target multiple pathways within both the adaptive and innate immune responses, which are crucial in managing infectious diseases, inflammatory disorders, and ischemia/reperfusion injuries. The company’s products are designed to address serious medical conditions with high morbidity and mortality, showing promising results in improving patient outcomes and reducing tissue damage during acute inflammatory events.
Enterome
Series B in 2014
Enterome SA is a biopharmaceutical company based in Paris, France, with an additional office in Cambridge, Massachusetts. Founded in 2008, the company specializes in developing innovative disease management solutions that leverage the understanding of the gut microbiome. Enterome focuses on creating biomarkers, companion diagnostics, and therapeutics targeted at microbiome-related diseases, including inflammatory bowel diseases and metabolic disorders. The company’s OncoMimic technology addresses cancer by mimicking tumor-associated antigens, thereby inducing a strong immune response against solid tumors. Enterome's drug candidates are designed to modulate the immune system and are currently advancing through clinical trials, with several programs in Phase 2 targeting challenging cancers such as glioblastoma, adrenal malignancies, and colorectal cancer. The company has formed a strategic collaboration with Takeda Pharmaceutical Company to enhance its research and development efforts.
Iconic Therapeutics
Series B in 2014
Iconic Therapeutics, Inc. is a biopharmaceutical company focused on developing innovative therapeutics for retinal diseases and cancer by leveraging tissue factor biology in processes such as angiogenesis and inflammation. The company's lead product, ICON-1, is a fusion protein designed to combat vision loss associated with age-related macular degeneration. Additionally, Iconic Therapeutics has developed hI-con1, a novel recombinant protein that targets tissue factor to activate the immune system, facilitating the destruction of pathological blood vessels linked to conditions like wet age-related macular degeneration and certain cancers. This approach not only promotes cell-mediated cytotoxicity but may also help reduce levels of vascular endothelial growth factor (VEGF), which plays a critical role in these diseases. Phase 1 clinical studies of hI-con1 have shown promising results without significant toxicities, indicating dose-related biological activity. Founded in 2002 and headquartered in South San Francisco, California, Iconic Therapeutics aims to transform scientific insights into effective treatments for serious health conditions.
scPharmaceuticals
Series A in 2014
scPharmaceuticals Inc. is a pharmaceutical company focused on developing and commercializing innovative therapeutic options for patients with serious medical conditions. The company’s lead product candidate, Furoscix, features a proprietary buffered formulation of furosemide delivered via the SmartDose drug delivery system, targeting congestion in patients with decompensated heart failure. In addition to Furoscix, scPharmaceuticals is advancing its product pipeline with scCeftriaxone, an antibiotic for infections from gram-positive and gram-negative organisms, and its scCarbapenem program, aimed at treating infections caused by gram-negative organisms. Founded in 2013 and headquartered in Burlington, Massachusetts, scPharmaceuticals aims to provide a convenient, safe, and effective alternative to intravenous drug administration through subcutaneous delivery, addressing the associated costs and risks. The company collaborates with West Pharmaceutical Services, Inc. to enhance the SmartDose system for Furoscix.
Thesan Pharmaceuticals
Series B in 2014
Thesan Pharmaceuticals, Inc. is a biopharmaceutical company based in Carlsbad, California, established in 2011. It specializes in developing innovative therapeutics for skin disorders, particularly atopic dermatitis and acne. Unlike many companies that primarily reformulate existing treatments with limited advancements, Thesan is dedicated to discovering and developing New Chemical Entities aimed at significantly improving patient outcomes. Through its commitment to innovation, Thesan seeks to address the gaps in dermatological care and provide healthcare providers with effective treatment options for their patients.
VHSquared
Series A in 2013
VHsquared Ltd. is a biotechnology company focused on developing oral biologics for immuno-inflammatory conditions affecting the gastrointestinal tract. Founded in 2010 and based in Cambridge, United Kingdom, VHsquared utilizes its proprietary Vorabody platform to create engineered domain antibodies that are resistant to degradation in the gut, allowing for effective oral administration. This innovative approach addresses the limitations of conventional antibodies, which are typically broken down in the gastrointestinal system. The company aims to produce a range of functional food products that target gastrointestinal infections and immune-mediated diseases, leveraging advancements in mucosal immunology and microbiota analysis. By developing therapies that are stable, specific, and locally active, VHsquared seeks to provide safer, more effective treatment options for patients with inflammatory bowel diseases and related conditions.
Cydan
Venture Round in 2013
Cydan is an orphan drug accelerator focused on developing therapies for patients with rare genetic diseases. The organization identifies and mitigates the risks associated with compounds that have therapeutic and commercial potential. Through a rigorous process, Cydan generates data to support the development of new therapies and the formation of new companies. Their experienced team leverages strong relationships with academia and patient advocacy groups, along with deep expertise in drug development and a proven track record of successful product commercialization. By guiding therapies through clinical, regulatory, and commercial development, Cydan aims to improve the lives of patients and families affected by rare diseases.
Acacia Pharma
Series B in 2013
Acacia Pharma Group plc, established in 2007, is a UK-based hospital pharmaceutical company specializing in the discovery, development, and commercialization of products for patients undergoing surgery, invasive procedures, or cancer chemotherapy. Its primary focus is on treating and preventing post-operative nausea and vomiting (PONV) and chemotherapy-induced nausea and vomiting (CINV). Acacia Pharma's lead product, BARHEMSYS, is an intravenous amisulpride for PONV treatment and prophylaxis. Other key products include APD403, an intravenous and oral amisulpride for CINV, and BYFAVO, an ultra-short-acting intravenous benzodiazepine sedative/anesthetic for use in invasive medical procedures. These products primarily serve anesthesiologists and oncologists.
DYSIS Medical
Venture Round in 2013
DYSIS Medical Ltd. is a medical device company based in Edinburgh, United Kingdom, specializing in imaging systems for the non-invasive, in-vivo detection of cancerous and pre-cancerous lesions. The company has developed the DYSIS Colposcope, a digital device that assesses the aceto-whitening reaction and presents the findings in an intuitive map format. In addition to the colposcope, DYSIS Medical offers a range of accessories, including both disposable and reusable specula, diathermy loops, and coagulation balls, as well as software for image data management and development of the DYSISmap. Founded in 2002 and rebranded in 2011, DYSIS Medical aims to improve early detection of cancers, potentially addressing significant healthcare challenges globally. The company maintains sales offices in Tampa, Florida; Edinburgh; and Athens, Greece.
River Vision Development
Series A in 2012
River Vision Development develops RV001, a protein therapy for the treatment of Graves’ Orbitopathy (GO). River Vision Development was founded in 2011 and is based in New York, New York.
Akamis Bio
Series B in 2012
Akamis Bio is a clinical-stage oncology company dedicated to advancing cancer treatment through its innovative Tumor-Specific Immuno-Gene Therapy (T-SIGn®) platform. The company develops a portfolio of therapeutics specifically targeting solid tumors, aiming to enhance patients' immune responses to recognize and eradicate cancer cells. By harnessing a proprietary intravenously administered viral platform, Akamis Bio focuses on delivering effective gene therapies that address the needs of cancer patients, striving to improve their quality of life and treatment outcomes.
BONESUPPORT
Venture Round in 2012
BONESUPPORT AB is a medical technology company based in Lund, Sweden, specializing in the development of injectable bioceramic bone graft substitutes aimed at treating fractures and bone voids resulting from trauma, infection, disease, or surgery. Founded in 1999, the company offers a range of products, including CERAMENT BONE VOID FILLER, CERAMENT G, and CERAMENT V. These products are designed to address various medical conditions such as chronic osteomyelitis and infected diabetic foot ulcers. CERAMENT G and CERAMENT V are antibiotic-eluting bone graft substitutes that enhance bone healing, utilizing gentamicin and vancomycin, respectively. BONESUPPORT operates additional locations in Frankfurt, Zurich, London, Boston, and Haryana, India, and is committed to improving the quality of life for patients with bone disorders through innovative biomaterial solutions.
AlloCure
Series B in 2012
AlloCure, Inc. is a biotechnology company focused on developing cell therapies for kidney diseases and related conditions. Founded in 2006 and based in Burlington, Massachusetts, with additional operations in Salt Lake City, Utah, and Hamburg, Germany, the company specializes in biologic therapies for acute kidney injuries and other serious illnesses. Central to AlloCure's approach is its unique technology that utilizes processed cells derived from human bone marrow, aiming to create off-the-shelf biological treatments for a range of debilitating diseases. The company was established based on the proprietary research of renowned scientists Dr. Christof Westenfelder and Dr. Axel Zander, who have dedicated their careers to advancing effective therapies for kidney-related ailments.
Enterome
Series A in 2012
Enterome SA is a biopharmaceutical company based in Paris, France, with an additional office in Cambridge, Massachusetts. Founded in 2008, the company specializes in developing innovative disease management solutions that leverage the understanding of the gut microbiome. Enterome focuses on creating biomarkers, companion diagnostics, and therapeutics targeted at microbiome-related diseases, including inflammatory bowel diseases and metabolic disorders. The company’s OncoMimic technology addresses cancer by mimicking tumor-associated antigens, thereby inducing a strong immune response against solid tumors. Enterome's drug candidates are designed to modulate the immune system and are currently advancing through clinical trials, with several programs in Phase 2 targeting challenging cancers such as glioblastoma, adrenal malignancies, and colorectal cancer. The company has formed a strategic collaboration with Takeda Pharmaceutical Company to enhance its research and development efforts.
Celladon
Venture Round in 2012
Celladon Corporation is a biotechnology company focused on developing molecular therapies for the treatment of heart failure. Founded in 2000 and headquartered in La Jolla, California, the company is known for its product candidates that address key enzyme deficiencies associated with advanced heart failure. One of its primary products, SERCA2a, is an enzyme that plays a crucial role in calcium cycling and contractility in heart muscle cells. Additionally, Celladon is developing MYDICAR, an enzyme replacement therapy aimed at improving heart function in patients suffering from heart failure.
Acacia Pharma
Series A in 2011
Acacia Pharma Group plc, established in 2007, is a UK-based hospital pharmaceutical company specializing in the discovery, development, and commercialization of products for patients undergoing surgery, invasive procedures, or cancer chemotherapy. Its primary focus is on treating and preventing post-operative nausea and vomiting (PONV) and chemotherapy-induced nausea and vomiting (CINV). Acacia Pharma's lead product, BARHEMSYS, is an intravenous amisulpride for PONV treatment and prophylaxis. Other key products include APD403, an intravenous and oral amisulpride for CINV, and BYFAVO, an ultra-short-acting intravenous benzodiazepine sedative/anesthetic for use in invasive medical procedures. These products primarily serve anesthesiologists and oncologists.
Nexstim
Venture Round in 2011
Nexstim Plc is a medical technology company based in Helsinki, Finland, specializing in non-invasive brain stimulation technologies. Founded in 2000, it focuses on developing and marketing navigated transcranial magnetic stimulation (nTMS) systems, utilizing its proprietary SmartFocus technology with 3D navigation for precise targeting of brain regions. The company offers the NBT system for treating major depressive disorder and chronic neuropathic pain, as well as the NBS system for pre-surgical mapping of speech and motor cortices. Nexstim primarily serves universities and teaching hospitals, with a significant portion of its revenue generated in North America and its products marketed across Europe and internationally.
DBV Technologies
Series C in 2011
DBV Technologies S.A. is a clinical-stage biopharmaceutical company based in Montrouge, France, dedicated to developing epicutaneous immunotherapy products aimed at treating food allergies. The company's lead candidate, Viaskin Peanut, has completed Phase III clinical trials for peanut allergies in children and adults. Additionally, DBV is developing Viaskin Milk, currently in Phase I/II trials for cow's milk protein allergy and related conditions, and Viaskin Egg, which is in pre-clinical stages for hen's egg allergy. The company also works on a booster vaccine for Bordetella pertussis and has earlier-stage research programs targeting respiratory syncytial virus, Crohn's disease, celiac disease, and type I diabetes. DBV Technologies collaborates with Nestlé Health Science to create MAG1C, a diagnostic patch test for non-IgE mediated cow's milk protein allergy in infants and toddlers. Founded in 2002, the company aims to provide safe and effective treatments for food allergies through its innovative Viaskin technology platform, which delivers biologically active compounds via the skin to activate the immune system.
Syntaxin
Series C in 2010
Syntaxin is a biopharmaceutical company that engineers and develops bacterial-based protein therapeutics for the treatment of neurological, inflammatory and endocrine diseases. The biopharmaceutical company's proprietary technology platform enables the engineering of bacterial proteins by domain substitution, to produce novel cell-specific biotherapeutics that inhibit cell secretion. These products can have therapeutic effects in a wide range of indications.
Asante Solutions
Series B in 2010
Asante Solutions is a Danish company founded over a decade ago, specializing in the development of medical devices aimed at improving diabetes management. With support from European venture capitalists, the company focused on creating innovative solutions for insulin delivery. Their flagship product, the Pearl Insulin Pump, features a system that utilizes pre-filled insulin cartridges, providing diabetic patients with a modern and efficient method for insulin administration. Through its advancements, Asante Solutions aims to simplify the daily management of diabetes for patients, enhancing their quality of life.
Spot something off? Help us improve by flagging any incorrect or outdated information. Just email us at support@teaserclub.com. Your feedback is most welcome.